The effect of calcitonin on growth hormone secretion in acromegaly.
To determine whether human calcitonin inhibits GH secretion in acromegaly, as previously described for healthy subjects, the effect of an i.v. bolus injection of calcitonin or saline on GH levels in patients with active acromegaly was studied and compared to that of an i.v. bolus injection of the synthetic somatostatin analogue, octreotide. After the injection of calcitonin, GH levels decreased by 46% of initial values, whereas octreotide reduced GH levels by 87% and saline had no significant effect. Administration of calcitonin to acromegalics did not cause the transient rise in plasma PRL and TSH levels seen in normal subjects. Octreotide induced a decrease in plasma PRL in three out of seven patients. It is concluded that human calcitonin suppresses GH secretion in acromegaly, but not to normal levels; moreover the effect is less than that found for octreotide. In addition, acromegalic patients did not exhibit the PRL and TSH-releasing activity of calcitonin found in normal subjects, while octreotide inhibited PRL secretion in some acromegalic patients.
Looij
B J
BJ
Department of Endocrinology, University Hospital, Leiden, The Netherlands.
Roelfsema
F
F
Frölich
M
M
D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D002116:Calcitonin / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005947:Glucose / Q000032:analysis; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000494:pharmacology; D011388:Prolactin / Q000032:analysis; D013972:Thyrotropin / Q000032:analysis
D011388:Prolactin; D013972:Thyrotropin; D013006:Growth Hormone; D002116:Calcitonin; D005947:Glucose; D015282:Octreotide